Prothena Corp. (NASDAQ:PRTA) shares rose 4.8% during trading on Wednesday . The company traded as high as $54.98 and last traded at $54.10, with a volume of 263,915 shares traded. The stock had previously closed at $51.61.

PRTA has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, June 22nd. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a research report on Friday, June 10th. Zacks Investment Research upgraded Prothena Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, April 21st. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research report on Tuesday, July 5th. Finally, Barclays PLC began coverage on Prothena Corp. in a research report on Friday, May 13th. They issued an “overweight” rating and a $60.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $74.60.

The company’s 50 day moving average price is $44.10 and its 200 day moving average price is $41.50. The stock’s market cap is $1.90 billion.

Prothena Corp. (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.04. On average, equities research analysts anticipate that Prothena Corp. will post ($3.72) EPS for the current fiscal year.

In related news, Director Dennis J. Selkoe sold 5,000 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the sale, the director now owns 3,025 shares of the company’s stock, valued at approximately $136,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Arthur W. Homan sold 9,375 shares of the stock in a transaction dated Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total value of $488,812.50. Following the sale, the insider now directly owns 9,375 shares in the company, valued at approximately $488,812.50. The disclosure for this sale can be found here.

A number of hedge funds recently modified their holdings of the company. State Board of Administration of Florida Retirement System boosted its stake in shares of Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock worth $1,182,000 after buying an additional 803 shares during the period. Nationwide Fund Advisors boosted its stake in shares of Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock worth $2,441,000 after buying an additional 15,683 shares during the period. Rhumbline Advisers boosted its stake in shares of Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock worth $2,098,000 after buying an additional 2,140 shares during the period. California Public Employees Retirement System boosted its stake in shares of Prothena Corp. by 214.0% in the fourth quarter. California Public Employees Retirement System now owns 91,700 shares of the company’s stock worth $6,246,000 after buying an additional 62,500 shares during the period. Finally, ProShare Advisors LLC boosted its stake in shares of Prothena Corp. by 11.1% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the company’s stock worth $2,037,000 after buying an additional 2,990 shares during the period.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.